Technologies
PDF


WARF: P120306US01

Producing Medical Isotopes with Dry-Phase Reactor


INVENTORS -

Thomas (Rock) Mackie, Thad Heltemes

OVERVIEWMedical isotopes like molybdenum-99 are used for imaging patients and treating disease. Today, most radioisotopes are produced in nuclear reactors outside of the United States that employ highly enriched uranium (HEU). This is a security concern because HEU can be made into nuclear weapons.

An alternative approach is to use low enriched uranium (LEU), which does not pose direct terrorist risks. In these systems, ions are injected into a gas chamber to generate neutrons that strike LEU material held in a nearby aqueous solution vessel, creating a chain reaction of isotope-producing collisions.

But safety remains a concern. Lots of fission energy is transferred to the water in these systems and maintaining stable power levels is difficult. Also, bubbles can form and explode, and gases must be recombined in a complex separate system.
THE INVENTIONUW–Madison researchers have developed an improved method for generating medical isotopes using a dry-phase granular uranium compound, such as uranium salt or oxide.

In the process, the dry granular uranium is exposed to radiation that produces medical isotopes by nuclear reaction. The irradiated uranium then is dissolved in a solvent and the desired isotopes are extracted using standard aqueous separation techniques. The granular uranium material can be dried and reused.
BUSINESS OPPORTUNITY
  • The Department of Energy has set the goal of meeting 100 percent of U.S. demand for the Mo-99 isotope without relying on highly enriched uranium.
APPLICATIONS
  • Production of medical isotopes
KEY BENEFITS
  • Avoids the problems of aqueous solutions
  • No risk of explosion in the production vessel
  • No pH control
  • Temperature stable
  • May operate critically or subcritically
  • Can operate at higher temperatures
  • More efficient cooling
  • Simplifies uranium handling
  • Mechanically simpler and less expensive
ADDITIONAL INFORMATION
For More Information About the Inventors
Contact Information
For current licensing status, please contact Jeanine Burmania at jeanine@warf.org or 608-960-9846.
The WARF Advantage

Since its founding in 1925 as the patenting and licensing organization for the University of Wisconsin-Madison, WARF has been working with business and industry to transform university research into products that benefit society. WARF intellectual property managers and licensing staff members are leaders in the field of university-based technology transfer. They are familiar with the intricacies of patenting, have worked with researchers in relevant disciplines, understand industries and markets, and have negotiated innovative licensing strategies to meet the individual needs of business clients.